Prescribing Information | Indication | Important Safety Information
View the NEW Overall Survival data TAGRISSO Logo
Dear Amy Gonsuron, 
After the publication of initial efficacy data from the 2017 FLAURA trial, TAGRISSO became a standard of care for patients with metastatic EGFRm NSCLC.
The FLAURA trial showed superior progression-free survival (PFS) for TAGRISSO with a median PFS of 18.9 months vs 10.2 months for erlotinib or gefitinib (HR=0.46 [95% CI: 0.37-0.57]; P<0.0001).1
New data show that first-line TAGRISSO extended median Overall Survival (OS) beyond 3 years—a significant benefit vs erlotinib/gefitinib.2
65% (n=180) of patients in the erlotinib/gefitinib arm received any second line therapy, of whom 47% (n=85) crossed-over to TAGRISSO.2
View the NEW Overall Survival data › 
FLAURA study design: Randomized, double-blind, active-controlled trial in 556 patients with metastatic EGFRm NSCLC who had not received prior systemic treatment for advanced disease. Patients were randomized 1:1 to either TAGRISSO
(n=279; 80 mg orally, once daily) or EGFR-TKI comparator (n=277; gefitinib 250 mg or erlotinib 150 mg orally, once daily). All US patients in the comparator arm received erlotinib. Crossover was allowed for patients in the EGFR-TKI comparator arm at confirmed progression if positive for the EGFR T790M resistance mutation. Patients with CNS metastases not requiring steroids and with stable neurologic status were included in the study. The primary endpoint of the study was PFS based on investigator assessment (according to RECIST v1.1). Secondary endpoints included OS, ORR, and DoR.1,3-4
CI, confidence interval; EGFR, epidermal growth factor receptor; EGFRm, epidermal growth hormone receptor mutation; HR, hazard ratio; NSCLC, non-small cell lung cancer; TKI, tyrosine kinase inhibitor.
There are no contraindications for TAGRISSO
Interstitial lung disease (ILD)/pneumonitis occurred in 3.9% of the 1142 TAGRISSO-treated patients; 0.4% of cases were fatal. Withhold TAGRISSO and promptly investigate for ILD in patients who present with worsening of respiratory symptoms which may be indicative of ILD (eg, dyspnea, cough and fever). Permanently discontinue TAGRISSO if ILD is confirmed
Heart rate-corrected QT (QTc) interval prolongation occurred in TAGRISSO-treated patients. Of the 1142 TAGRISSO-treated patients in clinical trials, 0.9% were found to have a QTc > 500 msec, and 3.6% of patients had an increase from baseline QTc > 60 msec. No QTc‑related arrhythmias were reported. Conduct periodic monitoring with ECGs and electrolytes in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval. Permanently discontinue TAGRISSO in patients who develop QTc interval prolongation with signs/symptoms of life threatening arrhythmia
Cardiomyopathy occurred in 2.6% of the 1142 TAGRISSO-treated patients; 0.1% of cardiomyopathy cases were fatal. A decline in left ventricular ejection fraction (LVEF) ≥10% from baseline and to <50% LVEF occurred in 3.9% of 908 patients who had baseline and at least one follow‑up LVEF assessment. Conduct cardiac monitoring, including assessment of LVEF at baseline and during treatment, in patients with cardiac risk factors. Assess LVEF in patients who develop relevant cardiac signs or symptoms during treatment. For symptomatic congestive heart failure, permanently discontinue TAGRISSO
Keratitis was reported in 0.7% of 1142 patients treated with TAGRISSO in clinical trials. Promptly refer patients with signs and symptoms suggestive of keratitis (such as eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain and/or red eye) to an ophthalmologist
Verify pregnancy status of females of reproductive potential prior to initiating TAGRISSO. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TAGRISSO and for 6 weeks after the final dose.
Advise males with female partners of reproductive potential to use effective contraception for 4 months after the final dose
Most common adverse reactions (≥20%) were diarrhea, rash, dry skin, nail toxicity, stomatitis, fatigue and decreased appetite
TAGRISSO is indicated for the first‑line treatment of patients with metastatic non‑small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA‑approved test.
Please see complete Prescribing Information including Patient Information.
You may report side effects related to AstraZeneca products by clicking here.
References: 1. TAGRISSO [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2018. 2. Ramalingam SS, Gray JE, Ohe Y, et al. Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis [oral presentation]. Presented at: European Society of Medical Oncology; September 27-October 1, 2019; Barcelona, Spain. Abstract LBA5. 3. Soria JC, Ohe Y, Vansteenkiste J, et al; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113-125. 4. Soria JC, Ohe Y, Vansteenkiste J, et al; FLAURA Investigators. Osimertinib in untreated EGFR‑mutated advanced non‑small‑cell lung cancer. N Engl J Med . 2018;378(2):113-125 [protocol].
This product information is intended for US Healthcare Professionals only.
TAGRISSO is a registered trademark of the AstraZeneca group of companies.
©2019 AstraZeneca. All rights reserved. US-32067 Last Updated 9/19
  AstraZeneca Logo
This email was sent to because you have an account with or are a valued partner of ION Solutions. If you no longer wish to receive these types of emails, please click here to unsubscribe or update your email preferences.
AmerisourceBergen - 1300 Morris Dr Chesterbrook PA, 19087
© 2019 ION Solutions. All Rights Reserved.